Devonian Health Group Inc. DVHGF
4.80 USD -1.08 (-18.30%)
Nov 3, 2026, 3:56 PM EST
4.80 Day range 4.80
4.27 52-week range 10.65
- YTD
- +12.41%
- 1 year
- +12.41%
News
prnewswire.com Devonian Health Group Receives Health Canada Authorization to Evaluate Novel Thykamine™ Formulation for Prevention of Radiation-Induced Skin Injury in Breast Cancer Patients New proprietary Thykamine™ 0.1% formulation expands Devonian's clinical development program into supportive oncology, with a potential differentiated regulatory pathway. KEY HIGHLIGHTS Significant…
gurufocus.com Devonian Health Group Provides Update on its Planned NYSE American Listing Devonian Health Group Provides Update on its Planned NYSE American ListingPR NewswireQUEBEC CITY, Oct. 16, 2026QUEBEC CITY, Oct. 16, 2026 /PRNewswire/ -- Devoni
prnewswire.com Devonian Health Group Provides Update on its Planned NYSE American Listing QUEBEC CITY, Oct. 16, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) today provides an update on its proposed listing on the NYSE American in…
prnewswire.com Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American QUEBEC, Sept. 11, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection with an underwritten public…
prnewswire.com Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay Validated HPLC-MS, NMR and a validated cell-based biological potency assay using the U937 human cell line, with MIP-1β as a biological marker of Thykamine™'s anti-inflammatory activity, provide…
prnewswire.com Devonian Health Group Anticipates to Commence Trading on the NYSE American QUEBEC, Aug. 18, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection with an underwritten public…
gurufocus.com Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering PR Newswire
prnewswire.com Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering QUÉBEC, July 27, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative…
prnewswire.com Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily…
gurufocus.com Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 PR Newswire
prnewswire.com Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 (all amounts are in Canadian dollars) Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per…
prnewswire.com Devonian Reports Results of its Annual General and Special Meeting of Shareholders QUÉBEC, March 30, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative…
prnewswire.com Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026 (all amounts are in Canadian dollars) Quarter ended January 31, 2026, net loss of $2.2 million dollars, ($0.81) per share Six months ended January 31, 2026, net loss of $3.8 million dollars, ($1.37)…
prnewswire.com Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects QUEBEC, Feb. 19, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating…
prnewswire.com Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls QUEBEC, Feb. 17, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced that a proprietary Thykamine™ fingerprint has been formally…
prnewswire.com Devonian reports additional molecular data from MASH liver study Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver QUÉBEC, Feb. 12, 2026…
prnewswire.com DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY Positive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine™ with anti-fibrotic effects in lungs Compelling results compared to Pirfenidone, a drug used to…
prnewswire.com DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT QUÉBEC, Feb. 2, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to…
prnewswire.com DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING QUÉBEC, Jan. 20, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that, in connection with an evaluation of an additional…
prnewswire.com Devonian Health Group Announces Grant of Stock Options QUEBEC , Dec. 19, 2025 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical Company specializing in the development of prescription…